Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures

See more here


Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform

Developing Programs to Focus on GI and Inflammation Therapies with Reduced, or No, Side Effects 

See more here


Pillo Health And BLACK+DECKER Partner To Deliver Smart Home Care Companion

See more here


Varian and Oncora Partner to Accelerate Precision Medicine in Radiation Oncology

See more here


VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

See more here


VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
РDemonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa 
– VNRX-5133 may provide a therapeutic option for these emerging pathogens, which are classified as urgent public health threats by the Centers for Disease Control and Prevention

See more here


Bainbridge Health Partners with Tabula Rasa HealthCare’s subsidiary DoseMe To Expand Medication Management Capabilities to Health Systems(s)

See more here


VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
Key Hires in Quality Assurance, Medical Sciences and Regulatory Affairs 

See more here


Group K Diagnostics and Health Network Laboratories Announce the Commencement of a Clinical Trial

See more here